Written answers

Tuesday, 26 April 2022

Department of Health

Medicinal Products

Photo of David CullinaneDavid Cullinane (Waterford, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

1807. To ask the Minister for Health the status of the inquiry and terms of reference for the drug sodium valproate; his plans to provide the disability package for those affected by sodium valproate; and if he will make a statement on the matter. [21053/22]

Photo of Patrick CostelloPatrick Costello (Dublin South Central, Green Party)
Link to this: Individually | In context | Oireachtas source

1831. To ask the Minister for Health when the inquiry into the historic use of sodium valproate, announced in October 2020, will take place; and if he will make a statement on the matter. [21143/22]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 1807 and 1831 together.

Department of Health officials are currently engaging with patient groups and other stakeholders regarding the terms of reference for an inquiry into the historical licensing and use of sodium valproate. The timeframe for the inquiry has yet to be decided. There is no specific package of supports available for people adversely affected by sodium valproate exposure in utero; however, the HSE has developed a diagnostic pathway for patients with suspected foetal valproate syndrome (FVS), as well as a pathway to community care services for those who receive a diagnosis of FVS. 

Comments

No comments

Log in or join to post a public comment.